Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T20761
|
||||
Former ID |
TTDNS00542
|
||||
Target Name |
Vascular endothelial growth factor A
|
||||
Gene Name |
VEGFA
|
||||
Synonyms |
VEGF-A; Vascular permeability factor; VPF; VEGFA
|
||||
Target Type |
Successful
|
||||
Disease | Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21] | ||||
Exudative age-related macular degeneration [ICD9: 362.5; ICD10: H35.3] | |||||
Lateral sclerosis [ICD10: G12.2] | |||||
Macular degeneration [ICD9: 362.5; ICD10: H35.3] | |||||
Metastatic colorectal cancer [ICD9: 153, 154; ICD10: C18-C21] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Function |
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. .
|
||||
BioChemical Class |
PDGF VEGF growth factor
|
||||
UniProt ID | |||||
Sequence |
MNFLLSWVHWSLALLLYLHHAKWSQAAPMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVD
IFQEYPDEIEYIFKPSCVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEM SFLQHNKCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVYVGARCCLMPWSLPG PHPCGPCSERRKHLFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR |
||||
Drugs and Mode of Action | |||||
Drug(s) | Aflibercept | Drug Info | Approved | Metastatic colorectal cancer | [551871] |
PTC299 | Drug Info | Phase 2 | Solid tumours | [522680] | |
RG7221 | Drug Info | Phase 2 | Colorectal cancer | [549449] | |
RO5520985 | Drug Info | Phase 2 | Colorectal cancer | [889398] | |
SNN-0029 | Drug Info | Phase 1/2 | Lateral sclerosis | [523531] | |
MP-0112 | Drug Info | Phase 1 | Macular degeneration | [522910] | |
SFLT-01 | Drug Info | Phase 1 | Macular degeneration | [522879] | |
Bevasiranib | Drug Info | Discontinued in Phase 3 | Exudative age-related macular degeneration | [550053] | |
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
HIF-1 signaling pathway | |||||
mTOR signaling pathway | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Pathways in cancer | |||||
Proteoglycans in cancer | |||||
MicroRNAs in cancer | |||||
Renal cell carcinoma | |||||
Pancreatic cancer | |||||
Bladder cancer | |||||
Rheumatoid arthritis | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
EGFR1 Signaling Pathway | |||||
TGF_beta_Receptor Signaling Pathway | |||||
TSH Signaling Pathway | |||||
Leptin Signaling Pathway | |||||
FSH Signaling Pathway | |||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | Glypican 1 network | ||||
HIF-2-alpha transcription factor network | |||||
Beta3 integrin cell surface interactions | |||||
S1P3 pathway | |||||
Signaling events mediated by TCPTP | |||||
S1P1 pathway | |||||
Alpha9 beta1 integrin signaling events | |||||
Integrins in angiogenesis | |||||
VEGFR1 specific signals | |||||
HIF-1-alpha transcription factor network | |||||
Reactome | Platelet degranulation | ||||
Regulation of gene expression by Hypoxia-inducible Factor | |||||
VEGF ligand-receptor interactions | |||||
VEGF binds to VEGFR leading to receptor dimerization | |||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Hypertrophy Model | |||||
Endochondral Ossification | |||||
Focal Adhesion | |||||
Differentiation Pathway | |||||
Bladder Cancer | |||||
Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | |||||
Nifedipine Activity | |||||
Aryl Hydrocarbon Receptor | |||||
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
Integrated Pancreatic Cancer Pathway | |||||
Oncostatin M Signaling Pathway | |||||
Allograft Rejection | |||||
Integrated Breast Cancer Pathway | |||||
Signaling by VEGF | |||||
Heart Development | |||||
Angiogenesis | |||||
References | |||||
Ref 522680 | ClinicalTrials.gov (NCT00911248) PTC299 for Treatment of Neurofibromatosis Type 2. U.S. National Institutes of Health. | ||||
Ref 522879 | ClinicalTrials.gov (NCT01024998) Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD). U.S. National Institutes of Health. | ||||
Ref 522910 | ClinicalTrials.gov (NCT01042678) Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema. U.S. National Institutes of Health. | ||||
Ref 523531 | ClinicalTrials.gov (NCT01384162) An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis. U.S. National Institutes of Health. | ||||
Ref 549449 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037469) | ||||
Ref 531341 | sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15. | ||||
Ref 532834 | Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2014 Oct;158(4):724-732.e2. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.